Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms

Status unconfirmed · Not applicable

Conditions studied: COVID-19

In brief

The objective of this study is to obtain data on the efficacy of the Vielight RX Plus in decreasing time to recovery of symptoms in subjects with COVID-19. The study will be conducted among COVID-19 positive subjects at home in self-isolation via electronic data collection (EDC). There will be no physical contact between the subjects and the Qualified Investigator (QI) or other study staff. This study aims to demonstrate that the Vielight RX Plus is a useful adjunct to standard of care (SOC). We hypothesize that the Vielight RX Plus will accelerate recovery and reduce viral infection severity.

Key facts

Study ID

NCT04418505

Run by

Vielight Inc.

People needed

295

Starts

2020-09-02

Expected to finish

2021-09-30

Last updated by the study team

2021-06-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmation of COVID-19 infection
• Experiencing moderate to severe respiratory symptoms
• Between 18-65 years of age

You may not qualify if…

• Need for hospitalization at the time of diagnosis
• Current need for supplemental oxygen or positive pressure support and/or has required supplemental oxygen or positive pressure support for >or= 24 hours
• >10 days since symptom onset
• Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
• Pregnant
• Positive for Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) or Human Immunodeficiency Virus
• Inability to electronically complete study questionnaires in English

Where it is running

• Progressive Medical Research — Port Orange, Florida, United States
• Dr. Michael Zahavi — Oshawa, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.